According to HSAs June 2025 approval notice, Tirzepatide KwikPen was approved in Singapore for weight management, including weight loss and weight maintenance, in adults with an initial BMI of at least 30, or BMI 27 to under 30 with at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes
Patients on both compounds should also monitor for fluid retention or joint discomfortknown effects of growth hormoneand report any new musculoskeletal symptoms to their healthcare team, as these may warrant dose adjustments or additional investigation
Before starting either medication, your provider will review your personal and family history of thyroid cancer, pancreatitis, gallbladder disease, kidney function, and pregnancy plans
Cahn A, Wiviott SD, Mosenzon O, et al
With a share price of approximately $40, NVO trades at 11x trailing earnings of $3.49 significantly lower than its three-year average of 26x, and less expensive than competitors such as LLY, ABBV, and JNJ
